Figure 1.
Current and possible future treatment options for CLL patients with TP53 dysfunction. HDMP, high-dose methylprednisolone; alloHCT, allogeneic hematopoietic cell transplantation; mAb, monoclonal antibody; NA, novel agent.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.